Prospects for Monoclonal Antibody Therapy in Pediatric Asthma
Purpose of Review
The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy.
Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do not respond to the current anti-IgE, anti-IL5, and anti-IL4/13 therapies.
Asthma is a heterogeneous disease which can be driven by different inflammatory mediators in different patients. To select the most effective biologic therapy for a pediatric patient, the asthma phenotype must first be determined. The steep cost of biologics limits their use, which makes proper pairing of patient to therapy even more crucial. Presently, several therapies exist for T2 high asthma, but it is hoped in the future that development of drugs effective for T2 low asthmatics will be available as well.
KeywordsAsthma Children Pediatrics Biologic therapy T2 high
Compliance with Ethical Standards
Conflict of Interest
The authors declare no conflicts of interest relevant to this manuscript.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance
- 3.Centers for Disease Control and Prevention. Asthma. 2018. https://www.cdc.gov/asthma/most_recent_data.htm. Accessed June 11, 2018.
- 5.Centers for Disease Control and Prevention. Asthma-related missed school days among children aged 5–17 years. 2018. https://www.cdc.gov/asthma/asthma_stats/missing_days.htm. Accessed June 11, 2018.
- 6.Centers for Disease Control and Prevention. Asthma’s impact on the nation. https://www.cdc.gov/asthma/impacts_nation/asthmafactsheet.pdf. Accessed June 11, 2018.
- 8.Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med. 1999;160(3):1001–8. https://doi.org/10.1164/ajrccm.160.3.9812110.CrossRefPubMedGoogle Scholar
- 11.• Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, et al. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: a systematic literature review. Allergy Asthma Proc. 2017;38(4):250–63. https://doi.org/10.2500/aap.2017.38.4067. Provided literature review of efficacy and safety of omalizumab, based on randomized control trials and real world studies. CrossRefPubMedGoogle Scholar
- 12.• Chipps BE, Lanier B, Milgrom H, Deschildre A, Hedlin G, Szefler SJ, et al. Omalizumab in children with uncontrolled allergic asthma: review of clinical trial and real-world experience. J Allergy Clin Immunol. 2017;139(5):1431–44. https://doi.org/10.1016/j.jaci.2017.03.002. Provided literature review of efficacy and safety of omalizumab, based on randomized control trials and real world studies. CrossRefPubMedGoogle Scholar
- 14.Xolair (omalizumab) Package Insert. 2017.Google Scholar
- 18.• Teach SJ, Gill MA, Togias A, Sorkness CA, Arbes SJ Jr, Calatroni A, et al. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. J Allergy Clinical Immunol. 2015;136(6):1476–85. https://doi.org/10.1016/j.jaci.2015.09.008. Described the potential efficacy of seasonal use of omalizumab CrossRefGoogle Scholar
- 24.Odajima H, Ebisawa M, Nagakura T, Fujisawa T, Akasawa A, Ito K, et al. Long-term safety, efficacy, pharmacokinetics and pharmacodynamics of omalizumab in children with severe uncontrolled asthma. Allergol Int. 2017;66(1):106–15. https://doi.org/10.1016/j.alit.2016.06.004.CrossRefPubMedGoogle Scholar
- 27.Busse W, Humbert M, Stephenson P, Iqbal A, Trzaskoma B, Conde L, et al. The effect of omalizumab on lung function in adolescents with moderate-to-severe allergic asthma. Am J Respir Crit Care Med. 2017;195:A5105.Google Scholar
- 28.ClinicalTrials.gov. Preventing Asthma in High Risk Kids (PARK). 2018. https://clinicaltrials.gov/ct2/show/NCT02570984. Accessed June 11, 2018.
- 31.Goldman M, Hirsch I, Zangrilli JG, Newbold P, Xu X. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the phase III SIROCCO and CALIMA studies. Curr Med Res Opin. 2017;33(9):1605–13. https://doi.org/10.1080/03007995.2017.1347091.CrossRefPubMedGoogle Scholar
- 32.Nucala (mepolizumab) Package Insert. 2017.Google Scholar
- 36.• Lugogo N, Domingo C, Chanez P, Leigh R, Gilson MJ, Price RG, et al. Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. Clinical therapeutics. 2016;38(9):2058–70.e1. https://doi.org/10.1016/j.clinthera.2016.07.010. Described the long-term efficacy and safety of mepolizumab in asthma, supporting the findings of the MENSA and SIRIUS studies by demonstrating maintenance of a lower OCS dose and lower asthma exacerbation rate. CrossRefPubMedGoogle Scholar
- 37.• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. https://doi.org/10.1016/s2213-2600(17)30125-x. Showed that mepolizumab was associated with significant improvements in health-related quality of life. CrossRefPubMedGoogle Scholar
- 38.• Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. https://doi.org/10.1016/j.chest.2016.03.018. Supported the prior findings that reslizumab did not result in clinically meaningful effects on lung function and symptom control in patients with baseline eosinophils < 400 cells/μL. CrossRefPubMedGoogle Scholar
- 39.Cinqair (reslizumab) Package Insert. 2016.Google Scholar
- 40.• Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/s2213-2600(15)00042-9. Showed that reslizumab improved outcomes in patients with inadequately controlled asthma who had blood eosinophil count ≥ 400 cells/μL by decreasing annual rate of exacerbations and improving time to first exacerbation, FEV1, asthma control scores, and quality of life scores. CrossRefPubMedGoogle Scholar
- 41.• Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2115–27. https://doi.org/10.1016/s0140-6736(16)31324-1. Showed that benralizumab reduced annual asthma exacerbation rates and improved lung function. CrossRefGoogle Scholar
- 42.• FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England). 2016;388(10056):2128–41. https://doi.org/10.1016/s0140-6736(16)31322-8. Supported prior findings that Benralizumab significantly lowered exacerbation rates and improved FEV1. CrossRefGoogle Scholar
- 45.• Farne HA, Wilson A, Powell C, Bax L, Milan SJ. Anti-IL5 therapies for asthma. Cochrane Database Syst Rev. 2017;9:Cd010834. https://doi.org/10.1002/14651858.CD010834.pub3. This Cochrane review supported the use of anti-IL-5 biologics, finding that all three currently available agents reduced exacerbation rates by 50%. PubMedCrossRefGoogle Scholar
- 46.• Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1804092. Showed that dupilumab reduced severe asthma exacerbations and improved lung function.
- 47.• Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1804093. Showed the steroid-sparing effect of dupilumab.
- 48.Hua F, Ribbing J, Reinisch W, Cataldi F, Martin S. A pharmacokinetic comparison of anrukinzumab, an anti-IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. Br J Clin Pharmacol. 2015;80(1):101–9. https://doi.org/10.1111/bcp.12589.CrossRefPubMedPubMedCentralGoogle Scholar
- 50.Popovic B, Breed J, Rees DG, Gardener MJ, Vinall LM, Kemp B, et al. Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Ralpha1 and IL-13Ralpha2. J Mol Biol. 2017;429(2):208–19. https://doi.org/10.1016/j.jmb.2016.12.005. CrossRefPubMedGoogle Scholar
- 51.Panettieri RA Jr, Sjobring U, Peterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir Med. 2018;6:511–25. https://doi.org/10.1016/s2213-2600(18)30184-x.CrossRefPubMedGoogle Scholar
- 52.Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–96. https://doi.org/10.1016/s2213-2600(16)30265-x.CrossRefPubMedGoogle Scholar
- 55.ClinicalTrials.gov. Study to evaluate tezepelumab in adults & adolescents with severe uncontrolled asthma (NAVIGATOR). 2017. https://clinicaltrials.gov/ct2/show/NCT03347279. Accessed May 26, 2018.
- 56.ClinicalTrials.gov. Study to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma (SOURCE). 2018. https://clinicaltrials.gov/ct2/show/NCT03406078. Accessed May 26, 2018.
- 57.Li J, Saruta K, Dumouchel JP, Magat JM, Thomas JL, Ajami D, et al. Small molecule mimetics of alpha-helical domain of IRAK2 attenuate the proinflammatory effects of IL-33 in asthma-like mouse models. J Immunol (Baltimore, Md: 1950). 2018;200(12):4036–43. https://doi.org/10.4049/jimmunol.1700693.CrossRefGoogle Scholar
- 59.ClinicalTrials.gov. Efficacy and safety study of GSK3772847 in subjects with moderately severe asthma. 2018. https://clinicaltrials.gov/ct2/show/NCT03207243.
- 60.GoodRx. Omalizumab. 2018. https://www.goodrx.com/omalizumab?drug-name=omalizumab. June 11, 2018.
- 61.Epocrates. Omalizumab. 2018. https://online.epocrates.com/drugs/3508/omalizumab. Accessed June 11, 2018.
- 65.GoodRx. Mepolizumab. 2018. https://www.goodrx.com/mepolizumab?drug-name=mepolizumab. Accessed June 11, 2018.